Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era

Brad Rybinski, a Aaron P Rapoport, b Ashraf Z. Badros, b Nancy Hardy, b Mehmet Kocoglu b

Abstract
We investigated whether prolonged lenalidomide treatment impairs stem cell collection among patients with multiple myeloma mobilized with plerixafor or cyclophosphamide. There was no correlation between the duration of lenalidomide therapy and the number of stem cells collected, suggesting that prolonged treatment with lenalidomide is not a significant barrier to stem cell collection in the context of modern mobilization regimens.

Introduction: Induction therapy for multiple myeloma is traditionally capped at 6 cycles of lenalidomide due to concerns that longer treatment compromises the ability to collect sufficient stem cells for autologous stem cell transplantation (ASCT). However, during the COVID-19 pandemic, many of our patients received prolonged lenalidomide induction due to concerns about proceeding to ASCT. We investigated whether prolonged induction with lenalidomide affects the efficacy of stem cell collection among patients mobilized with cyclophosphamide and/or plerixafor. Patients and methods: This single center, retrospective study included patients who were treated with lenalidomide induction regimens, received mobilization with cyclophosphamide or plerixafor, and underwent apheresis in preparation for ASCT. 94 patients were included, 40 of whom received prolonged induction with >6 cycles of lenalidomide-containing regimen. Results: Patients who received prolonged induction were more likely to require >1 day of apheresis (38% vs. 15%; OR 3.45; P = .0154), and there was a significant correlation between the duration of lenalidomide treatment and the apheresis time required to collect sufficient cells for transplant (R² = 0.06423, P = .0148). However, there was no significant difference between patients who received prolonged induction and those who did not with respect to CD34+ stem cell yields at completion of apheresis (9.99 vs. 10.46 cells/Kg, P = .5513) or on the first day of collection (8.29 vs. 9.59 cells/Kg, P = .1788). Conclusion: Among patients treated with >6 cycles of lenalidomide, mobilization augmented with cyclophosphamide and/or plerixafor will likely facilitate sufficient stem cell harvest to permit ASCT.

Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, No. 8, e716–e729 © 2022 Elsevier Inc. All rights reserved.
Keywords: Lenalidomide multiple myeloma, Autologous stem cell transplant, Stem cell harvest, Apheresis multiple myeloma, Apheresis time multiple myeloma

Introduction
Multiple myeloma (MM) is a neoplastic proliferation of plasma cells in the bone marrow that accounts for 1%-2% of malignancies in the United States. 1 The most commonly used induction regimen for MM consists of bortezomib, lenalidomide, and dexamethasone (VRd), which is often followed by high dose melphalan and stem cell rescue with autologous stem cell transplantation (ASCT). 2 More recently, carfilzomib, lenalidomide, and dexamethasone (KRd) has emerged as an effective alternative induction regimen, 3 and the anti-CD38 monoclonal antibody daratumumab has further improved...
induction responses. Regardless of the initial therapy, induction is typically limited to 3–6 cycles of a lenalidomide containing regimen for transplant eligible patients in order to permit successful CD34+ stem cell harvest and ASCT.2 High dose melphalan with ASCT significantly prolongs progression free survival (PFS) and overall survival (OS) compared to maintenance therapy alone, but ASCT requires peripheral-blood mobilization and collection of a sufficient number of CD34+ stem cells to facilitate recovery from high-dose chemotherapy. Early studies suggested that lenalidomide therapy impaired stem-cell collection, and therefore, induction is usually capped at 6 cycles to prevent prolonged lenalidomide exposure.

Marrow-resident CD34+ stem cells can be mobilized into the peripheral blood with exogenous administration of Granulocyte-Colony Stimulating Factor (G-CSF) and are thus able to be harvested with apheresis.14 G-CSF mobilization alone often yields an adequate peripheral blood CD34+ cell harvest, but early studies among patients mobilized with G-CSF identified an inhibitory effect of lenalidomide on stem cell collection. However, in those who fail to mobilize sufficient cells, or those who are predicted to mobilize poorly, the addition of cyclophosphamide prior to G-CSF mobilization or the addition of plerixafor, a CXCR4 antagonist, improves the chances of successful progenitor cell harvest.15 Mobilization with cyclophosphamide and/or plerixafor is routinely employed at our center, and we have had very few patients in whose collection of sufficient cells for transplant has failed. This is consistent with studies suggesting that use of cyclophosphamide and/or plerixafor enables the majority of lenalidomide treated patients to collect adequate cells for transplant, even among those treated with more than 6 cycles of lenalidomide. However, few studies have explored the impact of prolonged induction in substantial number of patients, and no studies have described the impact of prolonged induction in patients mobilized exclusively with the assistance of cyclophosphamide or plerixafor. Therefore, whether prolonged induction with more than 6 cycles of lenalidomide significantly impairs stem cell collection when rationale use of cyclophosphamide and/or plerixafor is employed remains unclear. As response to induction deepens with increasing cycles, whether there is a need to restrict the number of cycles of lenalidomide in order to permit ASCT is of significant clinical interest.

During the COVID-19 pandemic, the myeloma community has recommended delaying ASCT, which can extend induction therapy beyond the typical 3 to 6 months. In accordance with these recommendations, our institution performed no ASCTs for multiple myeloma patients in April or May of 2020, and the number of ASCTs performed in the following months was historically low as well. This created an unprecedented natural experiment in which a greater than expected number of patients received prolonged inductions with more than 6 cycles of lenalidomide containing regimen. In an effort to shorten hospital stays during the pandemic and shorten time spent in our infusion center, we also utilized plerixafor for stem cell mobilization more often. We therefore investigated, in a population of patients mobilized exclusively with the assistance of cyclophosphamide or plerixafor, whether prolonged induction with lenalidomide, defined as receiving more than 6 cycles of lenalidomide containing regimen, affected the efficacy of CD34+ stem cell collection. We hypothesized that prolonged induction would have minimal effect on CD34+ stem cell yields among cyclophosphamide or plerixafor treated patients, but that prolonged induction would likely suppress pre-apheresis cell counts and extend the apheresis time required to collect sufficient cells for transplant.

Patients and Methods

Study Design and Conduct

We conducted a retrospective, single center study to assess the impact of prolonged induction with lenalidomide, defined as treatment with >6 cycles of lenalidomide containing regimen, on CD34+ stem cell harvest in patients with multiple myeloma undergoing progenitor-cell apheresis for up-front consolidation with high dose melphalan and ASCT. One cycle of lenalidomide was defined as a 28-day period (with lenalidomide received for 21 out of 28 days) in which a patient received any treatment containing lenalidomide, such as VRd or KRd. Dose reductions of chemotherapy were permitted at the discretion of the prescribing physician. We collected data on the number of cycles of lenalidomide patients received prior to mobilized collection by apheresis, as well as data on patient characteristics which are known to or may plausibly affect stem cell collection. For outcome variables, we collected data on the total number of CD34+ cells collected at the completion of apheresis, the number of CD34+ cells collected on the first day of apheresis, and the length of time patients underwent apheresis. Data was collected by chart review of electronic medical records after approval from our Institutional Review Board (IRB) via IRB-exempt status.

Patients and Eligibility Criteria

Eligible patients were ≥ 18 years of age at the time of multiple myeloma diagnosis and underwent mobilization and apheresis to collect CD34+ cells for ASCT at the University of Maryland Greenebaum Comprehensive Cancer Center between October 1, 2019 and July 1, 2021. Eligible patients were mobilized with G-CSF in combination with cyclophosphamide, plerixafor, or both, per physician preference, following institutional protocols, with the goal of collecting sufficient cells for transplantation (target: 6 × 10^6 CD34+ cells/Kg; minimum 4 × 10^6 CD34+ cells/Kg). In patients who received cyclophosphamide mobilization, there was no limit on the number of apheresis sessions permitted to collect the target cell harvest; for patients who did not receive cyclophosphamide, a maximum of 2 apheresis sessions were employed. Patients were included in the analysis regardless of whether subsequent transplantation took place. Patients treated with 2 or more cycles of any regimen that did not include lenalidomide were excluded. This excluded several patients who had received more than 1 cycle of cyclophosphamide/bortezomib/dexamethasone (CyBorD) or more than 1 cycle of daratumumab/pomalidomide/dexamethasone (DPd).

Stem Cell Mobilization and Collection

As per our institutional standard, the choice of mobilization was made at the physician’s discretion, with an increased utilization of chemotherapy-free mobilization (using plerixafor only) employed early in the COVID-19 pandemic to minimize patient risk and optimize apheresis scheduling. Our standard regimens include G-CSF with plerixafor (G-P), dosed according to the Mozobil®
A Report From The Covid Era

Package Insert, and low-dose cyclophosphamide (1.5 grams/m²) followed by G-CSF 10 mcg/Kg/day through harvest by apheresis (Cy-G). Stem cell collection by apheresis with G-P began on Day 5 and continued through Day 6, if required. Collection after Cy-G began on or after Day 9, depending on peripheral blood CD34 cell (gCD34)-based predicted yield, and continued until the target was reached or diminishing daily yield predicted futility of further collections. The stem-cell target was predetermined by the prescribing physician based on institutional norms; our standard target for patients with multiple myeloma is 6 × 10⁹ CD34 cells/Kg for patients older than 60 years, and 10 × 10⁹/Kg for those 60 years and younger. A CBC was obtained for patients on the day prior to anticipated apheresis, ie, Day 4 with G-P mobilization and Day 8 with Cy-G; the gCD34 was also obtained when feasible (WBC of at least 2000/mm³) immediately prior to apheresis. The pre-apheresis WBC, pre-apheresis platelet count, and gCD34 were from these tests. In patients mobilized with Cy-G, plerixafor rescue was employed at the discretion of the collecting physician, generally if mobilization kinetics were sluggish or if the first day collection predicted a suboptimal total stem cell harvest.

Statistical Analysis

We used descriptive statistics to summarize continuous variables and we used counts and percentages to express categorical variables. Normality of continuous variables was assessed by the D’Agostino and Pearson test. Continuous variables which were normally distributed were compared using student’s t test (two tailed) or ANOVA, as appropriate, and variability was summarized using standard error of the mean. Continuous variables which were not normally distributed were compared using Mann-Whitney test and data was described as median (range) or 95% confidence intervals. We used Chi-square test or Fisher’s exact test, as appropriate, to compare counts of categorical variables. Correlation was assessed by univariate analysis in which we calculated the coefficient of determination (R²) and the P value of the slope. Outliers were identified by visual inspection of scatter plots. For multivariate analysis, whether a patient received multiple days of apheresis was considered a dichotomous variable, thus we utilized multivariate logistic regression to examine factors associated with multiple apheresis sessions. We utilized multivariate linear regression for the number of CD34⁺ cells collected, which was considered a continuous dependent variable. No co-variates included in the same model demonstrated significant collinearity, defined as R > 0.5 assessed by scatter plots prior to including them in the model. The variance inflation factors (VIFs) of all co-variates, included in all models, were less than 1.20. For all tests, a P value of < .05 was considered significant. Statistical analysis was performed using GraphPad Prism version 9.2.0.

Results

Patients and Collection

We identified 94 patients with multiple myeloma who were treated with a lenalidomide-containing induction regimen prior to G-CSF-mobilized CD34⁺ cell harvest by apheresis. All patients received cyclophosphamide, plerixafor, or both to augment mobilization. In our cohort, 54 patients (57%) received 4-6 cycles of lenalidomide, 30 patients (32%) received 7-8 cycles, and 10 patients (11%) received 9 or more cycles. The highest number of induction cycles received was 13. We separated patients into those who had received “Standard induction” (SI) with 4-6 cycles of lenalidomide (n = 54, 57%) and those who had received “Prolonged Induction” (Plind) with >6 cycles (n = 40, 43%). We compared clinical characteristics across cohorts (Table 1). Overall, cohorts were highly similar and were well balanced based on characteristics at diagnosis, including demographics (age, sex, race), markers of bone marrow function (marrow cellularity and plasma-cell replacement, and peripheral blood hemoglobin and platelet counts), and chemical markers of disease (eGFR, calcium, and LDH) (Table 1). Five patients in our study were older than 70 (1 aged 71 and 4 aged 72). ISS stage did not significantly differ between SI and Plind groups (Table 1). Fewer patients with high-risk disease received Plind, which neared statistical significance (43% vs. 25%, P = .0742); suggesting a hesitancy to extend induction in patients with high-risk disease.

Coincident diabetes, previously prior radiation therapy, and the presence of osteolytic lesions have been previously shown to negatively impact stem cell mobilization and collection. There were no significant differences in frequency of these characteristics between the SI or Plind cohorts (Table 1). The distribution of patients who received VRd, KRd, or both was similar between cohorts, and there was no significant difference in the frequency of patients who received daratumumab (Table 1). Cohorts were well balanced with respect to whether patients received cyclophosphamide, plerixafor, or both for mobilization (Table 1). Only 1 of 94 patient collections (1.1%) failed to provide the minimum number of CD34⁺ cells required for transplant (4 × 10⁶ CD34⁺ cells/Kg, our institutional standard). 67/94 (71%) of patients collected enough cells to safely undergo 2 transplants (8 × 10⁶ CD34⁺ cells/Kg), 23/94 patients (24%) of patients completed multiple days of apheresis. The majority of these patients (21/23) received 2 days of apheresis, though 1 patient received 3 days of apheresis and 1 patient received 4 days.

Clinical Characteristics and Pre-Apheresis Counts Correlate With Apheresis Time and CD34⁺ Cell Yield

We explored whether the duration of lenalidomide exposure affected stem cell collection outcomes by examining 3 parameters: the total number of CD34⁺ stem cells collected at the completion of apheresis (C₁), the number of CD34⁺ cells collected on the first day of apheresis (C₀), and the total minutes of apheresis that a patient completed across all apheresis sessions (AMin). C₁ provides a measure of whether apheresis collects sufficient cells to be successful but is highly influenced by the use of subsequent-day plerixafor when the first day-yield predicts an otherwise inadequate total harvest. Examining C₀ resolved this issue. C₁ and C₀ were measured in CD34⁺ cells x 10⁹ /Kg body weight. AMin, by measuring the total time patients undergo collection by apheresis, provides a measure of apheresis efficiency and cost, though ultimately its clinical significance is less than that of the stem-cell yield.

We first examined whether factors which have been previously established to affect collection outcomes correlated with C₁, C₀, or AMin in our data set. Factors which have been previously established to affect the success of CD34⁺ cell collection include age, bone marrow cellularity, pre-mobilization WBC, pre-apheresis
| Characteristic                          | Standard Induction (SI) | Prolonged Induction (PInd) | P value  |
|---------------------------------------|-------------------------|---------------------------|----------|
| Population, n (%)                     | 54 (57)                 | 40 (43)                   | .1461    |
| Median age (range), years             | 58 (28-72)              | 61 (44-72)                | .2561    |
| Mean age (SEM, n)                     | 56, (13, 54)            | 60, (11, 40)              | .1967    |
| Sex, n (%)                            | Male: 30 (56)           | Male: 23 (58)             | > .9999  |
|                                      | Female: 24 (44)         | Female:17 (42)            |          |
| Race, n (%)                           | White: 26 (48)          | White: 18 (45)            | .1787    |
|                                      | Black: 22 (41)          | Black: 20 (50)            |          |
|                                      | Asian: 5 (9)            | Asian: 0 (0)              |          |
|                                      | Latino: 1 (2)           | Latino: 2 (5)             |          |
| Bone marrow cellularity %, median (n) | 60 (30-100, 46)         | 60 (51-100, 37)           | .5512    |
| Bone marrow plasma cell %, median (n) | 70 (5-99, 51)           | 60 (5-100, 40)            | .4699    |
| Hemoglobin g/dL, median (SEM, n)      | 10.77 (0.36, 53)        | 11.05 (0.32, 39)          | .5846    |
| Platelets K/mcL, median (SEM, n)      | 217 (11.8, 53)          | 221 (8.5, 39)             | .8114    |
| Diabetes %, n (%)                     | Present: 9 (17)         | Present: 5 (12)           | .7708    |
|                                      | Absent: 45 (83)         | Absent: 35 (88)           |          |
| eGFR mL/min/1.73 m², median (n)       | > 60: 36 (67)           | > 60: 33 (81)             | .1025    |
|                                      | 30-60: 11 (20)          | 30-60: 4 (10)             |          |
|                                      | < 30: 3 (6)             | < 30: 0 (0)               |          |
| ISS Stage %, n (%)                    | Stage I: 22 (41)        | Stage I: 17 (43)          | .7910    |
|                                      | Stage II: 13 (24)       | Stage II: 14 (35)         |          |
|                                      | Stage III: 5 (9)        | Stage III: 5 (13)         |          |
| Osteolytic lesions %, n (%)           | Present: 30 (56)        | Present: 23 (58)          | > .9999  |
|                                      | Absent: 24 (44)         | Absent: 17 (42)           |          |
| Induction chemotherapy, n (%)         | VRd: 42 (78)            | VRd: 31 (78)              | .3605    |
|                                      | KRd: 9 (17)             | KRd: 4 (10)               |          |
| Radiation history, n (%)              | VRd and KRd: 3 (6)      | VRd and KRd: 5 (12)       |          |
|                                      | Present: 10 (19)        | Present: 11 (27)          | .3265    |
|                                      | Absent: 44 (61)         | Absent: 29 (73)           |          |
| Daratumumab exposure, n (%)           | Received: 4 (7)         | Received: 5 (12)          | .4884    |
|                                      | Did not receive: 50 (93)| Did not receive: 35 (88)  |          |
| Mobilization regimen %, n (%)         | Cyclophosphamide: 21 (39)| Cyclophosphamide: 17 (43)| .4650    |
|                                      | Plerixafor: 25 (46)     | Plerixafor: 14 (35)       |          |
|                                      | Cyclophosphamide + Plerixafor: 8 (15)| Cyclophosphamide + Plerixafor: 9 (23)|          |

*Standard induction (SI) was defined as 4-6 cycles of lenalidomide containing regimen. Prolonged induction (PInd) was defined as >6 cycles of lenalidomide containing regimen.

* Fisher’s exact test, chi square test, student’s t test, or Mann-Whitney test as appropriate.

* Although data was normally distributed, comparison of medians is also shown in accordance with convention. Age reflects patient age at first apheresis.

* Obtained or present at diagnosis.

* All mobilization regimens also utilized G-CSF.

Table 1: Patient Characteristics
and pre-mobilization platelet count, and peripheral CD34+ cell count, collected immediately prior to the first apheresis. Collection of pre-apheresis counts is routine practice at our institution, as peripheral CD34+ cell count can be used to identify patients requiring additional treatment with mobilization therapies. Results are shown in Table 2. Age at apheresis significantly correlated with reduced CT and C_D1 (R² = 0.08811, P = .0039 and R² = 0.05587, P = .0233, respectively). Platelet count prior to apheresis was significantly associated with increased C_D1 and reduced apheresis time (R² = 0.07505, P = .0082 and R² = 0.08847, P = .0042, respectively) but there was no significant correlation between platelet count and CT (R² = 0.005394, P = .4866) (Table 2). Higher peripheral CD34+ cell counts were significantly associated with increased CT and C_D1 (R² = 0.1073, P = .0015 and R² = 0.1863, P < .0001, respectively), as well as reduced A_min (R² = 0.1644, P < .0001). There was no significant correlation between pre-apheresis WBC or bone marrow cellularity and CT, C_D1, or A_min (Table 2). These findings support higher peripheral CD34+ cell and platelet counts, when obtained before apheresis, as predictors of harvest success, and advanced age as a predictor of less successful harvest.

With respect to additional characteristics which have been previously shown to affect apheresis, patients with and without a documented diagnosis of diabetes collected similar numbers of CD34+ stem cells in total and on the first day of apheresis, and they underwent apheresis for a similar number of minutes (10.16 vs. 10.81 cells x 10^6 /Kg, P = .5526, 9.07 vs. 8.69 cells x 10^6 /Kg, P = .7734, and 325 vs. 351 minutes, P = .9518, respectively). CT, C_D1, and A_min were also similar between patients who had prior radiation therapy and those who did not (10.28 vs. 10.18 cells x 10^6 /Kg, P = .9178, 8.87 vs. 9.50 x 10^6 cells/Kg, P = .5734, and 329 vs. 324 minutes, P = .4391, respectively). There was also no significant difference in CT, C_D1, or A_min between patients who did or did not have lytic lesions (9.65 vs. 10.72 x 10^6 cells/Kg, P = .1693, 8.91vs. 9.09 x 10^6 cells/Kg, P = .8435 and 325 vs. 324 minutes, P = .9380, respectively). Therefore, the effect of diabetes, radiation therapy, and lytic lesions on collection yield and apheresis time were not explored further.

Prolonged Lenalidomide Exposure is Associated With Decreased Pre-Apheresis Counts and Extended Apheresis Requirement

We next examined whether the length of lenalidomide exposure affects factors thought to impact apheresis yield and efficacy. As would be expected, there was no significant correlation between the number of cycles of lenalidomide a patient received and age at first apheresis or bone marrow cellularity at diagnosis (R² = 0.02070, P = .1666 and R² = 0.01563, P = .2602, respectively). However, patients who received Plnd had significantly lower pre-apheresis platelet counts than patients who received SI (mean 129 vs. 171 k/ml, P = .0103, Figure 1A). Likewise, there was a significant negative correlation between the number of cycles of lenalidomide a patient received and pre-apheresis platelet count (R² = 0.05691, P = .0206, Figure 1B). A similar pattern was seen in pre-apheresis WBC: patients who received Plnd had a lower WBC than patients who received SI (median 6.850 vs. 24.40 k/ml, P = .0063, Figure 1C), and longer lenalidomide induction correlated with reduced WBC (R² = 0.05765, P = .0212, median 6.850 vs. 24.40 k/ml, P = .0063, Figure 1C).
target. Patients who received Plnd underwent significantly longer apheresis than patients treated by SI (median 366 vs. 316.5 minutes, \( P = .0380, \) Figure 2A). There was also a significant positive correlation between the number of cycles of lenalidomide and minutes of apheresis (\( \Delta t_{\text{min}} \) (R\(^2 = 0.06423, P = .0148, \) Figure 2B).

Although SI and Plnd cohorts were well balanced with respect to the use of cyclophosphamide, plerixafor, or both (Table 1), analysis of whether duration of lenalidomide exposure prolonged apheresis independently of its impact on pre-apheresis counts would likely be complicated by the heterogeneity in mobilization strategies. Instead, we therefore investigated whether duration of lenalidomide exposure was associated with the likelihood of requiring 2 or more days of apheresis while controlling for age, bone marrow cellularity, and pre-apheresis peripheral CD34\(^+\) cell count (Table 3). By multivariate logistic regression analysis, only the number of cycles of lenalidomide and the pre-apheresis peripheral CD34\(^+\) cell count were independently associated with requiring more than 1 day of apheresis (Table 3). In particular, each additional cycle of lenalido-

---

**Figure 1A** Patients who received prolonged induction had reduced pre-apheresis platelet count. Bar graphs represent means with standard error of the mean. 4-6 cycles Lenalidomide Mean (SEM, n): 171 (11.7, 54). >6 cycles Lenalidomide Mean (SEM, n): 129 (9.5, 40). Students t test, 2 sided. * \( P < .05. P = .0103. \)
Figure 1B Lenalidomide exposure correlates with reduced pre-apheresis platelet count.

![Graph showing the correlation between cycles of Lenalidomide and platelets. The equation Y = -10.68*X + 225.3, R² = 0.05691, p = 0.0206 is provided.]

Figure 1C Patients who received prolonged induction had reduced pre-apheresis WBC. Bar graphs represent medians with 95% CI. 4-6 cycles Lenalidomide median (95% CI): 24.40 (8.90-30.00). >6 cycles Lenalidomide median (95% CI): 6.850 (5.20-14.70). Mann-Whitney test, 2 sided. ** P < .01. P = .0063.
...mide was associated with increased likelihood of requiring multiple days of apheresis (odds ratio = 1.581, 95% confidence interval 1.109-2.370).

Prolonged Lenalidomide Exposure Does Not Reduce Stem Cell Yield in Patients Mobilized With Cyclophosphamide or Plerixafor

To directly investigate the effect of duration of lenalidomide exposure on CD34+ cell yield, we examined the total CD34+ cells collected (C_T) and the CD34+ cells collected on the first day of apheresis (C_{D1}). There was no significant difference between patients who received 4-6 cycles of lenalidomide and Plnd with >6 cycles of lenalidomide in C_{D1} (mean 9.59 vs. 8.29, \(P = .1788\), Figure 2C) or C_T (mean 10.46 vs. 9.99, \(P = .5513\), Figure 2D). There was also no significant correlation between the number of cycles of lenalidomide and \(C_T\) (\(R^2 = 0.008344, P = .3812\)) or \(C_{D1}\) (\(R^2 = 0.02102, P = .1633\)). Further, SI and Plnd groups did not differ significantly in the frequency of patients collecting \(\geq 8 \times 10^6\) CD34+ cells/Kg, sufficient for 2 transplants per our institutional protocol (76% vs. 65%, respectively, \(P = .2599\)). Due to the heterogeneous mobilization strategies present in our cohorts, we also investigated whether the lack of effect of lenalidomide exposure on stem cell yields persisted when patients were grouped by mobilization strategy. Among those patients who received mobilization with plerixafor and G-CSF (39, 41%), there was still no significant difference between those patients who received SI or Plnd with respect to \(C_T\) (9.81 vs. 10.08 \(\times 10^6\) cells/Kg, \(P = .7897\)) or \(C_{D1}\) (7.43 vs. 8.63 \(\times 10^6\) cells/Kg, \(P = .3291\)). Likewise, there was no correlation between the number of cycles of lenalidomide and \(C_T\) (\(R^2 = 0.01180, P = .4255\)) or \(C_{D1}\) (\(R^2 = 0.02874, P = .2117\)). Among patients that received induction with cyclophosphamide and G-CSF (38, 40%), there was no significant difference between those patients who received SI or Plnd with respect to \(C_T\) (10.23 vs. 11.05 \(\times 10^6\) cells/Kg, \(P = .5249\)) or \(C_{D1}\) (9.44 vs. 11.00 \(\times 10^6\) cells/Kg, \(P = .2687\)). Likewise, there was no correlation between the number of cycles of lenalidomide received and \(C_T\) (\(R^2 = 0.004839, P = .6781\)) or \(C_{D1}\) (\(R^2 = 0.01488, P = .4656\)).

These findings suggest that ultimately, the impact of prolonged lenalidomide exposure on stem cell yield is minimal when mobilization is augmented with cyclophosphamide and/or plerixafor. However, although we did not observe a significant correlation between the duration of lenalidomide treatment and either \(C_T\) or \(C_{D1}\), there was a trend toward a negative correlation between \(C_{D1}\) and cycles of lenalidomide (\(R^2 = 0.02102, P = .1633\)). We therefore performed multivariate regression to further characterize the relationship between \(C_{D1}\) and cycles of lenalidomide.
Patients who received prolonged induction had longer apheresis time. Bar graphs represent medians with 95% CI. 4-6 cycles Lenalidomide median (95% CI): 316.5 (280-329). >6 cycles Lenalidomide median (95% CI): 366 (324-516). Mann-Whitney test, 2 sided. * $P < .05$. $P = .0380$.

Figure 2B Lenalidomide exposure correlates with apheresis time.
We selected age at first apheresis, pre-apheresis platelet count, and pre-apheresis peripheral CD34+ cell count as covariates, as each significantly correlated with CD34 cell yield in univariate analysis (Table 2).

We could not identify a significant effect of lenalidomide exposure on CD34, neither by the number of lenalidomide cycles ($\beta = -0.2411, P = .3004$) nor by PInd with $>6$ cycles of lenalidomide ($\beta = -0.6024, P = .4655$) (Table 4). Pre-apheresis platelet count and pre-apheresis peripheral CD34 count remained significant predictors of CD34+ in both models (Table 4). We also performed multivariate linear regression using the same set of predictors with $C_T$ as an outcome variable, although a correlation between $C_T$ and cycles of lenalidomide was not expected based on the results of univariate analysis ($P = .3812$). Neither the number of cycles ($\beta = -0.09715, P = .6300$) nor prolonged induction ($\beta = 0.01842, P = .9794$) predicted $C_T$ (Table 5). The effect of platelets was no longer significant, though age and pre-apheresis peripheral CD34+ cell count were significant predictors of total CD34+ stem cell yield (Table 5).

**Discussion**

Early in the COVID-19 pandemic, our center delayed mobilization and transplantation to minimize patient exposure and risk, and recommended continuing induction therapy. As the pandemic stretched on and we found we were able to safely support patients through mobilization and transplantation, our practice shifted back to standard induction. Thus, since the start of the pandemic, we have mobilized many patients after PInd and after SI, providing an opportunity to examine how the duration of lenalidomide induction affects CD34+ cell collection. Within a patient population mobilized exclusively with the assistance of plerixafor or cyclophosphamide, we found no compelling evidence that the duration of lenalidomide treatment affects CD34+ stem cell yields or that prolonged induction with $>6$ cycles of lenalidomide precludes successful collection of sufficient mobilized stem cells for transplant. However, we identified an association between longer lenalidomide induction and longer apheresis times, and longer lenalidomide exposure increased the risk of requiring more than one apheresis session.
Figure 2D: Prolonged induction did not affect total stem cell yield. Bar graphs represent means with standard error of the mean. 4-6 cycles Lenalidomide Mean (SEM): 10.46 (0.4958). >6 cycles Lenalidomide Mean (SEM): 9.99 (0.6128). Students t test, 2 sided. P = .5513.

4-6 cycles Lenalidomide
Mean (SEM): 10.46 (0.4958).

>6 cycles Lenalidomide
Mean (SEM): 9.99 (0.6128).

Table 4: Multivariate Linear Regression for Day 1 Apheresis Yield (C_D1)

| Day 1 Apheresis Yield (C_D1) Predicted By Cycles of Lenalidomide, Platelets, Age, And Peripheral CD-34 |
|---------------------------------------------------------------------------------------------------------|
| Independent Variable                                | β estimate (Standard Error) | P value |
| Cycles lenalidomide                                 | -0.2411 (0.2315)           | .3004   |
| Platelets (pre-apheresis)                           | 0.01565 (0.005245)         | .0037   |
| Age (at first apheresis)                            | 0.01265 (0.04827)          | .7938   |
| Peripheral CD34+ Cells (pre-apheresis)              | 0.04000 (0.006858)         | <.0001  |

Day 1 apheresis yield (C_D1) predicted by Prolonged or Standard induction, platelets, age, and peripheral CD-34

| Independent variable                                | β estimate (standard error) | P value |
|------------------------------------------------------|-----------------------------|---------|
| Standard Induction (4-6 cycles of L)                 | 1 (reference value)         | NA      |
| Prolonged Induction (> 6 cycles of L)                | -0.6024 (0.8218)            | .4655   |
| Platelets (pre-apheresis)                            | 0.01587 (0.005301)          | .0036   |
| Age (at first apheresis)                             | 0.01032 (0.048332)          | .8313   |
| Peripheral CD34+ Cells (pre-apheresis)               | 0.03980 (0.006879)          | <.0001  |
Our findings are consistent with a growing literature that suggests plerixafor and cyclophosphamide mobilize sufficient cells for transplant in the vast majority of patients, including those treated with prolonged lenalidomide induction. The initial studies describing a significant inhibitory effect of lenalidomide on stem cell collection were performed in patients mobilized mostly with G-CSF alone.\textsuperscript{7,11} Later studies that included patients who were treated with lenalidomide induction and mobilized with the addition of cyclophosphamide\textsuperscript{15-18} or plerixafor\textsuperscript{20-23} demonstrated a significant improvement in stem cell yield such that most patients were able to collect sufficient cells for transplant. These studies did not specifically investigate whether prolonged induction with lenalidomide affects stem cell collection, as lenalidomide induction is typically capped at 6 cycles. However, in another retrospective study, Cowan and colleagues recently reported their findings that higher lenalidomide exposure did not significantly reduce stem-cell yield following mobilization, whether with G-CSF alone or combined with chemotherapy or plerixafor.\textsuperscript{24} Our findings are consistent with their report. However, our study differed by only including patients mobilized with the addition of cyclophosphamide or plerixafor, and as such our results describe optimal collection yields that can be expected in the setting of prolonged induction. We also identified a relationship between prolonged lenalidomide exposure and the amount of apheresis time, whether measured in minutes or the number of apheresis sessions required to collect sufficient CD34\textsuperscript{+} cells. Prior studies have differed with respect to whether the duration of lenalidomide correlates with apheresis time,\textsuperscript{23,24} and it is possible that institutional specific factors contribute to the discrepancies.

The effect of prolonged lenalidomide treatment on successful stem cell mobilization and harvest for ASCT has significant clinical importance. Response to induction deepens with increasing cycles,\textsuperscript{25} which cautions against very short induction regimens. Recently, a large randomized phase III trial demonstrated that treatment with lenalidomide delays progression of intermediate- and high-risk smoldering multiple myeloma.\textsuperscript{37} Although patients were advised to collect stem cells for possible ASCT after 4-6 cycles of lenalidomide, the median number of cycles of lenalidomide patients ultimately received was greater than 20.\textsuperscript{37} As the results of this paradigm shifting trial are widely adopted, we can expect that more patients may present for stem-cell mobilization with significant lenalidomide exposure. Our findings still support early mobilization and collection of stem cells after 4-6 cycles of lenalidomide, as this will likely permit many to mobilize successfully without chemotherapy or plerixafor. Our findings also suggest that early mobilization will require fewer apheresis procedures. However, clinicians can be reassured by our results that augmented mobilization with chemotherapy and/or plerixafor will likely allow for successful stem-cell harvest even after prolonged lenalidomide exposure. Our report also suggests that moderate extension of induction therapy, in the setting of future pandemics or logistical obstacles, is unlikely to compromise the ability to collect sufficient stem cells for transplant.

Our work has the inherent limitations of a single-center retrospective analysis. It is possible that our study of 94 patients, including 40 who had prolonged lenalidomide-based induction with more than 6 cycles, was not adequately powered to detect small effect sizes. Only 10 patients received 9 or more cycles, and thus our results may be less applicable to patients who receive highly prolonged treatment with lenalidomide. Of note, there is a case report in which a patient who received 68 cycles of lenalidomide was successfully mobilized with G-CSF and plerixafor,\textsuperscript{39} which suggests that even exceptionally prolonged lenalidomide induction does not preclude successful mobilization and harvest. Our study included 5 patients older than 70, and our oldest patient was only 72 at the time of apheresis. ASCT significantly extends survival in patients 74 years of age or older,\textsuperscript{39} but since our study included no patients in this age group, our results may not be generalizable to this population. Nonetheless, in our analysis, age at first apheresis was significantly negatively associated with total stem cell yield, suggesting that efforts to optimize mobilization and collection, including mobilization early in the treatment course, employment of augmented mobiliza-
tion strategies, and planning for multiple-day collections, may be necessary to optimize successful harvest in patients with advanced age.

In conclusion, prolonged lenalidomide induction in patients mobilized with cyclophosphamide or plerixafor may increase the apheresis time required to collect sufficient CD34+ cells for ASCT but does not ultimately reduce the total number of stem cells collected. Our work provides reassurance that clinicians may extend lenalidomide induction, when necessary, without significantly compromising the ability to collect sufficient stem cells for transplant.

Clinical Practice Points

- Induction with lenalidomide impairs stem cell collection in multiple myeloma patients mobilized with G-CSF alone, and therefore lenalidomide induction is traditionally capped at 6 cycles. The addition of cyclophosphamide or plerixafor to mobilization regimens allows the majority of lenalidomide-treated patients to collect sufficient cells for autologous stem cell transplantation (ASCT). Whether prolonged induction with more than 6 cycles of lenalidomide significantly impairs stem cell collection in patients mobilized with cyclophosphamide or plerixafor has been inadequately explored.

- Initially, the COVID-19 pandemic created a need to defer mobilization and transplantation to minimize patient exposure and risk; this resulted in an opportunity to study the impact of prolonged lenalidomide induction on our ability to collect sufficient stem cells to permit ASCT following augmented mobilization with cyclophosphamide or plerixafor.

- Longer induction with lenalidomide was associated with longer apheresis times and a higher likelihood of requiring more than 1 session of apheresis to collect adequate CD34+ cells for ASCT. However, ultimately the CD34+ stem cell yield was not affected by the duration of lenalidomide exposure.

- Patients and clinicians can be re-assured that prolonged induction with lenalidomide is unlikely to compromise the ability to harvest sufficient stem cells for transplant, though longer apheresis time might be anticipated, and patients should receive plerixafor or cyclophosphamide as part of their mobilization regimen.

- Clinicians can expect that the majority of patients who receive prolonged courses of lenalidomide, due to treatment of smoldering myeloma, future pandemics, or patient preference will be able to collect sufficient cells for transplant.

Disclosure

The authors have stated that they have no conflicts of interest.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. doi:10.3322/caac.21442.
2. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548-567. doi:10.1002/ajh.25791.
3. Roussel M, Lauwers-Cancès V, Wuilleme S, et al. Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IMF KRd final results. Blood. 2021;138(2):113-121. doi:10.1182/blood.2021017044.
4. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936-945. doi:10.1182/blood.2020005288.
5. Palumbo A, Cavolo F, Gay F, et al. Autologous transplantation and management of myeloma. N Engl J Med. 2014;371(10):895-905. doi:10.1056/NEJMc1402888.
6. Gay F, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16(6):1617-1629. doi:10.1016/S1470-2045(15)00389-7.
7. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007;21(9):1808-1842. doi:10.1038/leu.2004.68.
8. Bhutani D, Zonder J, Valent J, et al. Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma. Support Care Cancer. 2013;21(9):2437-2442. doi:10.1007/s00520-013-1808-5.
9. Mazumder A, Kaufman J, Niesvizky R, et al. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia. 2008;22(8):1280-1281. doi:10.1038/leu.2008.308.
10. Cavolo F, Bringhen S, Milone G, et al. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. Leukemia. 2011;25(10):1627-1631. doi:10.1038/leu.2011.130.
11. Popat U, Saliba R, Thandi R, et al. Impact of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009;15(6):718-723. doi:10.1016/j.bbmt.2009.02.011.
12. Patapai H, Stewart AK, Cabou S, et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia. 2008;22(6):1282-1284. doi:10.1038/leu.2008.308.
13. Arora S, Majhiel NS, Liu H. Hematopoietic progenitor cell mobilization for autologous stem cell transplantation in multiple myeloma in contemporary era. Clin Lymphoma Myeloma Leuk. 2019;19(4):200-205. doi:10.1016/j.clml.2018.12.010.
14. Poortrogio M, Adel N, Landau H, et al. Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center. Bone Marrow Transplant. 2013;48(8):1033-1039. doi:10.1038/bmt.2012.281.
15. Zannetti BA, Saraceni F, Cellini C, et al. Low-dose cyclophosphamide versus intermediate-high-dose cyclophosphamide versus granulocyte colony-stimulating factor alone for stem cell mobilization in multiple myeloma in the era of novel agents: a multicenter retrospective study. Transplant Cell Ther. 2021;27(3):e244.e1–e244.e8. doi:10.1016/j.jtct.2020.12.009.
16. Nahta A, Cook R, Vogl DT, et al. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen. Bone Marrow Transplant. 2011;46(1):59-63. doi:10.1038/bmt.2010.63.
17. Wang L, Xiang H, Yan Y, et al. Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis. Ann Hematol. 2021;100(2):563-573. doi:10.1007/s00277-020-04376-w.
18. Silvennoinen R, Anttila P, Säily M, et al. A randomized phase II study of stem cell mobilization with cyclophosphamide-G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma. Bone Marrow Transplant. 2016;51(3):372-376. doi:10.1038/bmt.2015.236.
19. DiPietro JF, Studmaier EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720-5726. doi:10.1182/blood-2008-08-179446.
20. Malard F, Köger N, Gabriel H, et al. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine and lenalidomide. Biol Blood Marrow Transplant. 2012;18(2):314-317. doi:10.1016/j.bbmt.2011.10.005.
21. Speroff S, Peter R, Wäschler D, et al. Patients’ outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis. Transfus Clin. 2017;57(1):115-121. doi:10.1111/trf.13883.
22. Shah EE, Young RP, Wong SW, et al. Impact of plerixafor use at different peripheral blood CD34+ thresholds on autologous stem cell collection in patients with multiple myeloma. Biol Blood Marrow Transplant. 2020;26(5):876-883. doi:10.1016/j.bbmt.2019.11.024.
23. Cowan AJ, Stevenson PA, Green DJ, et al. Prolonged lenalidomide therapy does not impact autologous peripheral blood stem cell mobilization and collection in multiple myeloma patients: a single-center retrospective analysis. Transplant Cell Ther. 2021;27(8):661.e1-661.e6. doi:10.1016/j.jtct.2021.04.010.
24. Rosol O, Oriol A, Rios R, et al. Borzomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019;134(15):1387-1385. doi:10.1182/blood.2019002641.
25. Al Saeed AS, Sher T, Gertz MA. Multiple Myeloma in the Time of COVID-19. Acta Haematol. 2020;143(5):410-416. doi:10.1159/000507690.
27. Terpos E, Engelhardt M, Cook G, et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). *Leukemia*. 2020;34(8):2000–2011. doi:10.1038/s41375-020-0876-z.

28. Malard F, Mohry M. Management of patients with multiple myeloma during the COVID-19 pandemic. *Lancet Haematol*. 2020;7(6):e435–e437. doi:10.1016/s2352-3026(20)30124-1.

29. Jethava E, Fonseca R, Landgren O. Management of multiple myeloma during COVID-19 pandemic. *Leuk Res Rep*. 2020;14. doi:10.1016/j.lrr.2020.100212.

30. Ferraro F, Lympéri S, Méndez-Ferrer S, et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. *Sci Transl Med*. 2011;3(104):104ra101. doi:10.1126/scitranslmed.3002191.

31. Sauer S, Erdmann K, Jensen AD, et al. Local radiation therapy before and during induction delays stem cell mobilization and collection in multiple myeloma patients. *Transplant Cell Ther*. 2021;27(10):876.e1–876.e11 876.e871-876.e811. doi:10.1016/j.jtct.2021.06.025.

32. Jung SH, Yang DH, Ahn JS, et al. Advanced myeloma is a poor mobilization factor in peripheral blood stem cell collection in patients with multiple myeloma. *J Clin Apher*. 2014;29(6):305–310. doi:10.1002/jca.21326.

33. Ozkurt ZN, Yegin ZA, Suyani E, et al. Factors affecting stem cell mobilization for autologous hematopoietic stem cell transplantation. *J Clin Apher*. 2010;25(5):280–286. doi:10.1002/jca.20246.

34. Bakeer M, Zubair AC, Roy V. Low baseline platelet count predicts poor response to plerixafor in patients with multiple myeloma undergoing autologous stem cell mobilization. *Cyttherapy*. 2020;22(1):16–20. doi:10.1016/j.cyt.2019.10.008.

35. Hündenner M, Engelhardt M, Bruckner T, et al. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma. *J Clin Apher*. 2014;29(6):299–304. doi:10.1002/jca.21323.

36. Duong HK, Bolwell BJ, Rybicki L, et al. Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: a simple method using day 1 CD34+ cell yield. *J Clin Apher*. 2011;26(3):111–115. doi:10.1002/jca.20278.

37. Lonial S, Jacobus S, Fonseca R, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. *J Clin Oncol*. 2020;38(11):1126–1137. doi:10.1200/jco.19.01740.

38. Agarwal R, Abidi MH. Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma. *Hematol Rep*. 2012;4(4):e26. doi:10.4081/hr.2012.e26.

39. Joseph NS, Gupta VA, Wyman S, et al. Benefits of autologous stem cell transplantation for elderly myeloma patients in the last quarter of life. *Transplant Cell Ther*. 2021. doi:10.1016/j.jtct.2021.09.024.